Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS R MURPHY

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1144275827
CMS profile
97323
Location
CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$170,908.10

248 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $76,834.35 117
Genentech USA, Inc. $33,025.72 30
GlaxoSmithKline, LLC. $14,052.88 13
F. Hoffmann-La Roche AG $12,329.05 13
GENZYME CORPORATION $11,641.31 15
Regeneron Healthcare Solutions, Inc. $7,546.95 18
Novartis Pharmaceuticals Corporation $4,931.02 8
OptiNose US, Inc. $4,783.44 11
Genentech, Inc. $3,413.94 10
ALK-Abello, Inc $2,222.72 8
SANOFI-AVENTIS U.S. LLC $49.00 2
Intersect ENT, Inc. $42.40 1
Kaleo, Inc. $18.26 1
PFIZER INC. $17.06 1

Page 5 of 5; records 201–248 of 248 matching records. This page contains 48 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS R MURPHY

NPI 1144275827 · CMS profile ID 97323

Allopathic & Osteopathic Physicians / Allergy & Immunology

CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–248 of 248 matching records. This page contains 48 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144275827?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS R MURPHY, NPI 1144275827, CMS profile ID 97323. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–248 of 248 matching records. This page contains 48 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144275827?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). THOMAS R MURPHY, NPI 1144275827, CMS profile ID 97323. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–248 of 248 matching records. This page contains 48 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144275827?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
THOMAS R MURPHY, NPI 1144275827, CMS profile ID 97323, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–248 of 248 matching records. This page contains 48 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1144275827?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

248 matching records · $170,908.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 248 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–248 of 248.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $588.8603/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681256524 CMS
Genentech USA, Inc. $2,150.0003/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681274963 CMS
Genentech USA, Inc. $132.0903/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681285095 CMS
Genentech USA, Inc. $588.8703/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681286791 CMS
Genentech USA, Inc. $2,150.0003/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681298307 CMS
Genentech USA, Inc. $588.8603/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681318133 CMS
AstraZeneca Pharmaceuticals LP $1,400.0003/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688760113 CMS
AstraZeneca Pharmaceuticals LP $3,700.0003/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688761451 CMS
Novartis Pharmaceuticals Corporation $12.8103/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659935375 CMS
Regeneron Healthcare Solutions, Inc. $78.1402/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445315 CMS
AstraZeneca Pharmaceuticals LP $106.5802/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688757131 CMS
AstraZeneca Pharmaceuticals LP $25.2602/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688759011 CMS
AstraZeneca Pharmaceuticals LP $66.9802/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688768035 CMS
OptiNose US, Inc. $39.4602/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684243637 CMS
OptiNose US, Inc. $2,000.0002/22/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684243377 CMS
OptiNose US, Inc. $38.0002/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684243511 CMS
OptiNose US, Inc. $36.7402/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684243513 CMS
AstraZeneca Pharmaceuticals LP $3,700.0002/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688751841 CMS
AstraZeneca Pharmaceuticals LP $1,400.0002/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688761371 CMS
Genentech USA, Inc. $22.9202/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681309203 CMS
AstraZeneca Pharmaceuticals LP $1,400.0002/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688766847 CMS
AstraZeneca Pharmaceuticals LP $122.0802/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688753811 CMS
AstraZeneca Pharmaceuticals LP $10.8302/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688754453 CMS
AstraZeneca Pharmaceuticals LP $0.4402/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688761713 CMS
AstraZeneca Pharmaceuticals LP $30.0401/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688757039 CMS
AstraZeneca Pharmaceuticals LP $123.9501/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688763415 CMS
AstraZeneca Pharmaceuticals LP $675.7401/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688764603 CMS
AstraZeneca Pharmaceuticals LP $295.1701/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688766599 CMS
GlaxoSmithKline, LLC. $3,600.0001/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671450959 CMS
AstraZeneca Pharmaceuticals LP $319.9601/29/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688749977 CMS
AstraZeneca Pharmaceuticals LP $124.2601/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688759387 CMS
ALK-Abello, Inc $16.1501/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698047921 CMS
GlaxoSmithKline, LLC. $106.0801/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671392470 CMS
AstraZeneca Pharmaceuticals LP $11.1701/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688770753 CMS
Genentech USA, Inc. $3,440.0001/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681183621 CMS
Genentech USA, Inc. $90.8601/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681288693 CMS
Genentech USA, Inc. $222.8801/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681289327 CMS
Genentech USA, Inc. $299.0001/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681295103 CMS
Genentech USA, Inc. $2,150.0001/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681295801 CMS
Genentech USA, Inc. $485.5001/17/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681296697 CMS
Genentech USA, Inc. $3,440.0001/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681300593 CMS
Genentech USA, Inc. $118.2001/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681197787 CMS
Genentech USA, Inc. $60.8401/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681227122 CMS
Genentech USA, Inc. $3,440.0001/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681235101 CMS
Genentech USA, Inc. $3,440.0001/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681262794 CMS
Genentech USA, Inc. $46.4801/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681293739 CMS
GENZYME CORPORATION $23.1601/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693893627 CMS
GlaxoSmithKline, LLC. $13.9101/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671417949 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $170,908.10 248
PY2020 $43,054.08 47
PY2021 $54,216.69 97
PY2022 $70,461.57 136
PY2023 $87,164.88 152
PY2024 $110,627.92 163
PY2025 $116,516.84 206

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $377,862.10 205
PY2024 Principal investigator $214,243.59 369
PY2023 Recipient $1,745.56 6
PY2023 Principal investigator $112,362.98 79
PY2022 Recipient $2,157.00 2
PY2022 Principal investigator $65,569.45 58
PY2021 Recipient $5,565.67 3
PY2021 Principal investigator $15,137.70 4
PY2020 Principal investigator $5,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

205 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Paratek Pharmaceuticals, Inc. $8,537.00 12/05/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1181711252
Principal investigator 1 Paratek Pharmaceuticals, Inc. $27,623.00 11/14/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1181711248
Principal investigator 1 Paratek Pharmaceuticals, Inc. $12,500.00 11/13/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1181711234
Principal investigator 1 Paratek Pharmaceuticals, Inc. $10,858.00 11/13/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1181711242
Principal investigator 1 Paratek Pharmaceuticals, Inc. $12,371.00 11/12/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1181711228
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $737.51 11/03/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184257169
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $737.51 11/03/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184257171
Principal investigator 1 Incyte Corporation $1,083.60 10/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501547
Principal investigator 1 Incyte Corporation $1,970.00 10/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501550
Principal investigator 1 Incyte Corporation $2,462.00 10/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501557
Principal investigator 1 Incyte Corporation $2,462.00 10/24/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501562
Principal investigator 1 Novartis Pharmaceuticals Corporation $191,291.87 10/08/2025 Non-covered Recipient Entity
CHARLESTON ENT AND ALLERGY
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190308368
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $737.51 10/03/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184244949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $737.51 10/03/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184244951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $737.51 10/03/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184244953
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $266.70 10/03/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184244955
Principal investigator 1 Incyte Corporation $22.90 10/01/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501554
Principal investigator 1 Incyte Corporation $125.71 10/01/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501566
Principal investigator 1 Optinose US, Inc. $13,907.00 09/03/2025 Non-covered Recipient Entity
Charleston ENT Associates, LLC
A 12-Week Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 mcg of OPN-375 Twice a Day (BID) in Adolescent Subjects With Chronic Rhinosinusitis Without Nasal Polyps No dispute reported 06/30/2026 1163251985
Principal investigator 1 Incyte Corporation $1,303.00 08/13/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501528
Principal investigator 1 Incyte Corporation $1,970.00 08/13/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501537
Principal investigator 1 Incyte Corporation $1,875.00 08/13/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501540
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 07/18/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184217463
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/18/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184217465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 07/18/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184217467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/18/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184217469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/18/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184217471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 07/18/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184217473
Principal investigator 1 Incyte Corporation $1,500.00 07/16/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501532
Principal investigator 1 Incyte Corporation $1,875.00 07/16/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501544
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 07/07/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184213339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $435.91 07/02/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184212471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $435.91 07/02/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184212473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $435.91 07/02/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184212475
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210050
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210056
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210058
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210068
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20.25 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210108
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210162
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210164
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29.70 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210196
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210198
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210200
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210202
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210212
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33.75 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210214
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210250
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210256
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210258
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210260
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210262
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210266
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210270
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210272
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210274
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210276
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210278
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210280
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210282
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210286
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210288
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210290
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210292
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210294
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210296
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $36.45 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210298
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210300
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 06/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184210302
Principal investigator 1 Incyte Corporation $1,933.00 06/18/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501436
Principal investigator 1 Incyte Corporation $2,462.00 06/18/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501440
Principal investigator 1 Incyte Corporation $1,300.20 06/18/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $737.51 06/18/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184207965
Principal investigator 1 Incyte Corporation $30.72 06/03/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501496
Principal investigator 1 Incyte Corporation $2,003.00 05/12/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501444
Principal investigator 1 Incyte Corporation $1,286.90 05/12/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501448
Principal investigator 1 Incyte Corporation $2,003.00 05/12/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501514
Principal investigator 1 Incyte Corporation $48.54 05/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501476
Principal investigator 1 Incyte Corporation $2.94 05/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501480
Principal investigator 1 Incyte Corporation $251.42 05/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501484
Principal investigator 1 Incyte Corporation $80.15 05/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501492
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $435.91 04/28/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $435.91 04/28/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $435.91 04/28/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $435.91 04/28/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $737.51 04/23/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184185621
Principal investigator 1 Incyte Corporation $1,078.80 04/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501428
Principal investigator 1 Incyte Corporation $2,003.00 04/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501432
Principal investigator 1 Incyte Corporation $1,970.00 04/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501452
Principal investigator 1 Incyte Corporation $1,875.00 04/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501503
Principal investigator 1 Incyte Corporation $2,003.00 04/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501506
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $266.70 04/04/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184181674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $737.51 04/04/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184181676
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $266.70 04/04/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184181678
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $737.51 04/04/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184181680
Principal investigator 1 Incyte Corporation $74.34 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501456
Principal investigator 1 Incyte Corporation $8.82 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501460
Principal investigator 1 Incyte Corporation $45.80 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501464
Principal investigator 1 Incyte Corporation $22.89 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501468
Principal investigator 1 Incyte Corporation $251.42 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501472
Principal investigator 1 Incyte Corporation $29.76 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501488
Principal investigator 1 Incyte Corporation $173.55 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501500
Principal investigator 1 Incyte Corporation $22.89 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501518
Principal investigator 1 Incyte Corporation $22.89 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501521
Principal investigator 1 Incyte Corporation $22.89 04/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501525
Principal investigator 1 Incyte Corporation $1,933.00 03/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501336
Principal investigator 1 Incyte Corporation $1,879.50 03/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501344
Principal investigator 1 Incyte Corporation $2,591.00 03/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501420
Principal investigator 1 Incyte Corporation $2,003.00 02/19/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501312
Principal investigator 1 Incyte Corporation $2,071.00 02/19/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501316
Principal investigator 1 Incyte Corporation $2,338.00 02/19/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501320
Principal investigator 1 Incyte Corporation $1,161.50 02/19/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501412
Principal investigator 1 Incyte Corporation $2,592.00 01/17/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501324
Principal investigator 1 Incyte Corporation $1,875.00 01/17/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501328
Principal investigator 1 Incyte Corporation $1,199.20 01/17/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501332
Principal investigator 1 Incyte Corporation $2,199.00 01/17/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501348
Principal investigator 1 Incyte Corporation $2,462.00 01/17/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501392
Principal investigator 1 Incyte Corporation $2,199.00 01/17/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501424
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $737.51 01/15/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) No dispute reported 06/30/2026 1184147581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $609.36 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145644
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $609.36 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145646
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $435.91 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145648
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $731.00 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145650
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $420.03 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145652
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $420.03 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145654
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $389.04 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145656
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $435.91 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145658
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $420.03 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145660
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $420.03 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145662
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $420.03 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145664
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $420.03 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145666
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $420.03 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145668
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $435.91 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145670
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $609.36 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145672
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $420.03 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $609.36 01/06/2025 Non-covered Recipient Entity
CHARLESTON ENT ASSOCIATES LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184145676
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,785.40 01/03/2025 Non-covered Recipient Entity
ENT AND ALLERGY PARTNERS
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT No dispute reported 06/30/2026 1185545955
Principal investigator 1 Incyte Corporation $58.56 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501340
Principal investigator 1 Incyte Corporation $289.25 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501352
Principal investigator 1 Incyte Corporation $11.76 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501356
Principal investigator 1 Incyte Corporation $37.44 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501360
Principal investigator 1 Incyte Corporation $123.90 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501364
Principal investigator 1 Incyte Corporation $45.80 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501368
Principal investigator 1 Incyte Corporation $29.76 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501372
Principal investigator 1 Incyte Corporation $74.34 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501376
Principal investigator 1 Incyte Corporation $115.62 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501380
Principal investigator 1 Incyte Corporation $16.18 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501384
Principal investigator 1 Incyte Corporation $251.42 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501388
Principal investigator 1 Incyte Corporation $38.15 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501396
Principal investigator 1 Incyte Corporation $38.15 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501400
Principal investigator 1 Incyte Corporation $38.15 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501404
Principal investigator 1 Incyte Corporation $38.15 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501408
Principal investigator 1 Incyte Corporation $123.90 01/02/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CENTER OF CHARLESTON
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy, and Safety Study of Povorcitinib in Participants With Chronic Spontaneous Urticaria No dispute reported 06/30/2026 1240501416

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2021 Amount invested $28,751.00 1
PY2021 Value of interest $30,272.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

1 record · PY2021

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2021 The North Carolina Mutual Wholesale Drug Company Inc $28,751.00 $30,272.00 stock Physician Covered Recipient No dispute reported 06/30/2026 845598703